Hormonal contraception and thrombosis

Any review must carefully weigh the available evidence

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f2250 (Published 16 April 2013)
Cite this as: BMJ 2013;346:f2250

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Dustin J Costescu, contraceptive advice research and education fellow1,
  2. Ashley Waddington, contraceptive advice research and education fellow1
  1. 1Department of Obstetrics and Gynaecology, Queen’s University, Kingston, ON, Canada K7L 2V7
  1. dustin.costescu{at}queensu.ca

Helmerhorst and Rosendaal’s recommendation that women prescribed oral contraceptives should receive levonorgestrel and 30 µg of ethinylestradiol is based on the observation that thrombosis risk is related to ethinylestradiol amount and progestogen type.1 Although interesting, this strategy is not adequately evidence based.

Retrospective database studies of contraception and thrombosis are often cited because they are inexpensive and can rapidly amass large datasets. Unfortunately, conclusions are …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL